Web Analytics

3 Latest Announced Rounds

$1,325.73M Raised in 74 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Capstan Therapeutics

start up
United States - San Diego, California
  • 21/03/2024
  • Series B
  • $175,000,000

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNP) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com.


Related People